We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

114 hedge funds and large institutions have $39.6M invested in SANGAMO THERAPEUTICS INC in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $34.5M → $39.6M (+$5.15M)

8.02% more ownership

Funds ownership: 23.39%31.41% (+8%)

4% more call options, than puts

Call options by funds: $756K | Put options by funds: $727K

6% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 32

7% less funds holding

Funds holding: 122114 (-8)

29% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 24

Holders
114
Holders Change
-8
Holders Change %
-6.56%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
17
Increased
30
Reduced
32
Closed
24
Calls
$756K
Puts
$727K
Net Calls
+$29K
Net Calls Change
+$104K
Name Holding Trade Value Shares
Change
Change in
Stake
YAG
1
Yorkville Advisors Global
New Jersey
$11.9M +$13.1M +22,000,000 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$5.07M
WA
3
Wasatch Advisors
Utah
$4.38M +$722K +1,215,653 +18%
Renaissance Technologies
4
Renaissance Technologies
New York
$3.7M +$2.18M +3,671,327 +116%
BlackRock
5
BlackRock
New York
$2.6M -$378K -636,310 -12%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.26M +$29K +48,829 +2%
GCP
7
GSA Capital Partners
United Kingdom
$1.22M +$760K +1,279,247 +132%
Charles Schwab
8
Charles Schwab
California
$694K +$109K +183,965 +17%
IC
9
Ikarian Capital
Texas
$682K -$356K -600,000 -32%
UBS Group
10
UBS Group
Switzerland
$676K +$379K +638,043 +104%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$653K +$183K +307,479 +34%
Two Sigma Investments
12
Two Sigma Investments
New York
$475K +$53.6K +90,334 +11%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$458K -$268K -451,252 -35%
State Street
14
State Street
Massachusetts
$453K -$170K -286,492 -26%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$419K -$615K -1,036,284 -57%
HighTower Advisors
16
HighTower Advisors
Illinois
$403K -$9.44K -15,895 -2%
Invesco
17
Invesco
Georgia
$368K +$117K +196,558 +41%
Squarepoint
18
Squarepoint
New York
$338K +$365K +614,233 +5,687%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$315K +$11.5K +19,400 +3%
Morgan Stanley
20
Morgan Stanley
New York
$310K -$103K -172,993 -23%
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$282K +$307K +516,517 +10,318%
Macquarie Group
22
Macquarie Group
Australia
$217K
Northern Trust
23
Northern Trust
Illinois
$214K -$1.28K -2,157 -0.5%
GSEP
24
Golden State Equity Partners
California
$212K +$11.9K +20,000 +5%
Millennium Management
25
Millennium Management
New York
$197K -$480K -807,945 -69%

SGMO Hedge Fund Activity: Q2 2025 in Review

114 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2025, worth a combined $39.6M — up 15% from $34.5M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of SGMO and 17 opened new positions — a net loss of 7 holders — while 32 trimmed existing stakes and 30 added.

The largest buyer was Renaissance Technologies, adding an estimated $2.18M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.31M sold.

  • 114 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2025, down from 122 in Q1 2025.
  • Funds reported $39.6M of SANGAMO THERAPEUTICS INC stock for Q2 2025, up 15% quarter-over-quarter.
  • 17 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2025 and 24 closed out, a net change of -7 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q2 2025 was Renaissance Technologies, an estimated $2.18M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q2 2025 was Point72 Asset Management, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2025.